Supernus Pharmaceuticals Inc [SUPN] stock is trading at $40.00, up 7.07%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SUPN shares have gain 2.17% over the last week, with a monthly amount glided 9.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on January 06, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $57. Previously, Piper Sandler downgraded its rating to Neutral on September 11, 2024, and dropped its price target to $36. Jefferies upgraded its rating to a Buy and raised its price target to $40 on April 13, 2021. Piper Sandler upgraded its rating to Overweight for this stock on June 16, 2020, and upped its price target to $31.
Supernus Pharmaceuticals Inc [SUPN] stock has fluctuated between $25.53 and $39.88 over the past year. Currently, Wall Street analysts expect the stock to reach $36 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $40.00 at the most recent close of the market. An investor can expect a potential drop of -10.0% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
Supernus Pharmaceuticals Inc [NASDAQ:SUPN] reported sales of 651.97M for the trailing twelve months, which represents a growth of 14.17%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.06 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.92 points at the first support level, and at 37.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.66, and for the 2nd resistance point, it is at 41.32.
Ratios To Look Out For
For context, Supernus Pharmaceuticals Inc’s Current Ratio is 2.20. In addition, the Quick Ratio stands at 1.98 and the Cash Ratio stands at 0.11. Considering the valuation of this stock, the price to sales ratio is 3.39, the price to book ratio is 2.19 and price to earnings (TTM) ratio is 37.45.
Transactions by insiders
Recent insider trading involved Bhatt Padmanabh P., Sr. VP of IP, CSO, that happened on Jan 27 ’25 when 2573.0 shares were sold. Sr. VP of IP, CSO, Bhatt Padmanabh P. completed a deal on Jan 28 ’25 to sell 700.0 shares. Meanwhile, Officer PADMANABH BHATT bought 22000.0 shares on Jan 27 ’25.
